36 / 38
Early deaths (<3 mo.): characteristics
Single Baseline Characteristics by OS With Nivolumab
CheckMate 057: Nivolumab vs Docetaxel in Previously Treated NSQ NSCLC
Patients with factor in
OS subgroup (%)
OS ≤3 months
OS >3 months
<3 mo
from
last TX
PD
best
resp.
No
maint.
TX
>5 sites
with
lesions
Bone
mets
Liver
mets
Never
Current/
former
0
1
<1%
≥1%
≥5% ≥10%
EGFR
mut.-pos.
Prior
therapy
Smoking
status
Baseline
disease site
PD-L1
expression
a
ECOG
PS
Rapid PD
High Tumor
Burden
Poor PS
Peters – WCLC 2016